EGFR tyrosine kinase inhibitors (TKIs) have been used as adjuvant therapy after tumor resection as multiple randomized trials have demonstrated their effectiveness, as first‐line treatment for EGFR exon 19 deletions or exon 21 L858R mutations of NSCLC patients. This evidence concerns the gene EGFR and neoplasm.